CIK 0001517022
- Large accelerated filer
Akebia Therapeutics, Inc.
Sign in to watch- Ticker
- AKBA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 208756903
- Phone
- +1 617-871-2098
- Business address
- 180 THIRD AVENUE, FLOOR 2, WALTHAM, MA, 02451
- 4 Grant or award SVP, Chief Development Officer acquired 23,000 shares (grant or award)
- 4 Grant or award SVP and Chief Medical Officer acquired 23,500 shares (grant or award)
- 4 Grant or award SVP, General Counsel, Sec. acquired 28,500 shares (grant or award)
- 4 Grant or award CEO and President acquired 119,500 shares (grant or award)
- 4 Grant or award SVP, CFO & Treasurer acquired 30,000 shares (grant or award)
- 5 Insider Annual Insider Trading Report
- 4 Exercise or conversion CEO and President acquired 20,000 shares (option exercise)
- 4 Open-market sale SVP, Chief Business Officer sold 1,629 shares at $10.49 ($17,089)
- 4 Open-market sale Director sold 1,980 shares at $10.46 ($20,711)
- 4 Open-market sale SVP, General Counsel, Sec. sold 1,810 shares at $10.49 ($18,988)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Director sold 1,981 shares at $8.96 ($17,746)
- 4 Open-market sale SVP, Chief Business Officer sold 1,401 shares at $8.95 ($12,546)
- 4 Open-market sale SVP, General Counsel, Sec. sold 1,556 shares at $8.95 ($13,934)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Director sold 1,980 shares at $7.48 ($14,819)
- 4 Open-market sale SVP, Chief Business Officer sold 1,402 shares at $7.47 ($10,468)
- 4 Open-market sale SVP, General Counsel, Sec. sold 1,557 shares at $7.47 ($11,625)
Page 14 of 19 · 378 filings